SKITUDE
4.6.2019 16:46:10 CEST | Business Wire | Press release
The merger of Skitude, the largest network of skiing apps, and the Skioo innovative skipass technology, which provides access to ski resorts with a single card and no waiting in line, aims to optimise sales channels for the more than 150 partnering ski resorts for the upcoming season.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190604005775/en/
Alongside may other advantages, the strategy will consist of using post-payment systems to facilitate the user’s skiing experience, streamlining their access to the slopes, and helping the ski resorts position their products on their online platform.
“We are working so that skiers can purchase a ski pass ahead of time and load the ticket on their RFID card, or validate beforehand using a credit card, easily from their mobile on”, explained Skitude CEO Marc Bigas. “These principles of convenience and post-payment are already well-known thanks to popular services like Uber”, he added.
As a result, Skitude Chairman Yngve Tvedt explains, the combined digital platform will add a new dimension to the ski industry with a digital journey that is simpler and fun.
Thus, Tvedt assures, Skitude is participating in the “digitalisation of the sector” and agrees with Marc Bigas that this experience will offer “more convenience to the skier” as well as “powerful solutions for the mobile sales channels and marketing services” that will help ski resorts stay better connected with the needs of their current and potential customers.
New challenges
The merger of the two companies is also aimed at finding a way to push back against the stagnation of users in the industry, one of the sector's main challenges. “We are setting off on a journey to meet challenges using technology”, the company’s CEO stated, adding that the experience built up by both Skitude and Skioo over the years will become “valuable information for ski resorts”.
It is worth noting that the Girona-based company has always been committed to interacting with users “before, during and after their visit”, which, according to Bigas, “strengthens the competitiveness of the industry and enables it to continue moving forward”.
A community of more than 1.3 million skiers
The Skitude community is currently made up of more than 1.3 million skiers who have used the free applications that are compatible with the Skitude platform, most of them being the official applications of ski resorts.
It is a very active community. Thanks to the GPS Tracker that can log their runs, users have already logged activity at more than 1,200 ski resorts in 45 countries worldwide, and have been able to participate in more than 250 Challenges allowing them to win ski days, equipment like skis, boots or action cameras, and exclusive discounts.
The operation will allow consolidating the international project of 50 people, with offices in Girona, Lausanne and Oslo, and to continue researching to find dynamic solutions and improve the customer experience at ski resorts.
The shareholders of the company are comprised of the entrepreneurial partners Marc Bigas and David Huerva, Spanish investment funds, as well as the three Norwegian funds that own Skioo: Investinor, Canica and Norselab. Norselab counts the Olympic alpine ski champion Aksel Lund Svindal as an investor.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190604005775/en/
Contact:
For more information: Àric Monterde +34-972-001-021 aric.monterde@skitude.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom